

## Anti-CD30 Antibody (Brentuximab)

### Introduction

Brentuximab is an antibody-drug conjugate (ADC) consisting of a monoclonal antibody and an anti-tubulin drug. Its monoclonal antibody is derived from humanized IgG1 and targets the CD30 molecule. It internalizes and releases cytotoxic drugs after binding to CD30, thereby destroying cancer cells. Brentuximab is mainly used to treat Hodgkin's lymphoma and systemic anaplastic large cell lymphoma.

### Product parameters

Alternative Names	Brentuximab Vedotin, Adcetris
Target Accession	-
Target	CD30
CAS number	2088770-90-3
Molecular Weight	145.38 kDa
Host	CHO
Reactivity	Chimeric
Conjugation	Unconjugated
Form	Liquid
Concentration	1 mg/mL
Buffer System	100 mM Pro 20 mM Arg pH 5.0.
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	-
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

## Note

1. This product is for scientific research use only.



**APExBIO Technology**

**[www.apexbt.com](http://www.apexbt.com)**

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: [info@apexbt.com](mailto:info@apexbt.com)

